Category: FDA

1 7/11/2017

Fact-checking pharma: 5 cancer drug myths, busted

1 1/26/2017

Approval of ‘breakthrough’ hepatitis C drugs isn’t even half the story; now come the harms

1/9/2017

Whitewashing a black box warning: The Chantix story that didn’t get told

11 12/6/2016

With media watchdogs on the sidelines, pharma-funded advocacy groups pushed Cures Act to the finish line  

1 11/29/2016

Off-label drug marketing: Who will decide what’s “truthful” when the evidence can’t be trusted?   

10/31/2016

Early report card on quality of FDA news releases: C at best

10/25/2016

Black box warnings for ‘lifesaving’ hepatitis C drugs highlight systematic misinformation

3 9/28/2016

What some stories missed about the muscular dystrophy drug approval: Pharma’s close ties to vocal patient advocacy groups

3 6/22/2016

What’s at stake in the FDA’s decision on eteplirsen, an experimental muscular dystrophy drug

6/13/2016

21st Century Cures Act nears passage with little news media scrutiny